We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.
- Authors
Schmidt, M.; Bachhuber, A.; Victor, A.; Steiner, E.; Mahlke, M.; Lehr, H. A.; Pilch, H.; Weikel, W.; Knapstein, P. G.
- Abstract
Purpose. Paclitaxel is an important agent in the pharmacological treatment of metastatic breast cancer. Despite its efficacy in selected patients, the majority of patients have a resistance against paclitaxel. The aim of this study was to identify the responding patients and hence prevent the other patients from ineffective treatment. Identifying these patients could spare them an ineffective treatment and could in turn characterize a subgroup of patients with a higher response rate. Material and methods. Thirty-three patients with metastatic breast cancer received paclitaxel 175 mg/m2 either as first- (15 patients) or as second-line (18 patients) treatment. Immunohistochemistry was performed on the blocks of the primary tumors with monoclonal antibodies against p53, HER-2/neu, P-glycoprotein, Glutathione-S-Transferase-π, and β-tubulin II. The expression of those factors was then correlated with the objective response to paclitaxel. Results. Ten of 33 patients had an objective response to treatment. A significant correlation with the objective response was found for the expression of p53. None of the tumors with p53 expression (n=11) responded to paclitaxel. In contrast, 10 of the 22 patients without p53 expression showed an objective response (P=0.013). Expression of HER-2/neu, P-glycoprotein, Glutathione-S-Transferase-π, and β-tubulin II did not show a correlation with the response to paclitaxel. Conclusion. The immunohistochemical detection of p53 characterizes patients with metastatic breast cancer unlikely to respond to paclitaxel.
- Subjects
BREAST cancer; PACLITAXEL; CANCER treatment; P53 antioncogene; THERAPEUTICS; DIAGNOSIS; ONCOLOGY
- Publication
Journal of Cancer Research & Clinical Oncology, 2003, Vol 129, Issue 5, p295
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-003-0430-1